Among doctors, Google outpaces professional search engines

Share this article:

Even among physicians, Dr. Google reigns supreme. Double the number of MDs used the consumer search engine (87%) for professional research online as the next most-used search options (WebMD and PubMed, each at 43%), data from a recent survey show.

Google was one of six consumer search options (out of 12 mentioned in the survey) drawing significant usage; each was tapped by an average of 23% of doctors. That's the same percentage that used each of the six medical sites on average, researchers from Kantar Media found.

 

The data come from Kantar's Sources & Interactions 2011 survey, a study of healthcare professionals' touch points with pharma and professional media. In the physicians study, 2,983 US-based physicians were surveyed by mail and online during the first half of 2011 to document what professional sources of information they rely on.

 

Kantar also found wide variations in reported usage based on specialty, age and other demographic factors. Google and Yahoo! were consistent performers across most groups, Kantar said, generally within a two- or three-point range of average. For other sites, usage varied. Only 29% of family medicine doctors rely on PubMed, but 77% of infectious disease specialists do.

Older users tended to gravitate toward PubMed and Google Scholar, while the younger set more often tapped general search engines Yahoo! and Bing, as well as WebMD and MDLinx.

Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.